Attenuation of doxorubicin-induced cardiotoxicity by tadalafil: A long acting phosphodiesterase-5 inhibitor

Molecular and Cellular Pharmacology

Volumn 2, Issue 5, 2010, Pages 173-178

  Koka, Saisudha ^a   Kukreja, Rakesh C ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cardiomyopathy; cGMP; Doxorubicin; Phosphodiesterase inhibitors; PKG; ROS

Indexed keywords

DOXORUBICIN; PHOSPHODIESTERASE V; SILDENAFIL; TADALAFIL;

APOPTOSIS; ARTICLE; CANCER SURVIVAL; CARDIOMYOPATHY; CARDIOTOXICITY; DRUG MECHANISM; DRUG RESPONSE; ENZYME INHIBITION; HEART PROTECTION; HUMAN; NONHUMAN; OXIDATIVE STRESS; SPINAL CORD INJURY;

EID: 78651519019     PISSN: None     EISSN: 19381247     Source Type: Journal    
DOI: 10.4255/mcpharmacol.10.23     Document Type: Article

References (38)

1. Bristow MR, Billingham ME, Mason JW, Daniels JR. Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep 1978;62:873-9.
2. Hortobagyi GN. Anthracyclines in the treatment of cancer. An overview. Drugs 1997;54 Suppl 4:1-7.
3. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973;32:302-14.
4. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56:185-229.
5. Singal PK, Li T, Kumar D, Danelisen I, Iliskovic N. Adriamycin-induced heart failure: mechanism and modulation. Mol Cell Biochem 2000;207:77-86.
6. Fu LX, Waagstein F, Hjalmarson A. A new insight into adriamycin-induced cardiotoxicity. Int J Cardiol 1990;29:15-20.
7. Arai M, Yoguchi A, Takizawa T et al. Mechanism of doxorubicin-induced inhibition of sarcoplasmic reticulum Ca(2+)-ATPase gene transcription. Circ Res 2000;86:8-14.
8. Arola OJ, Saraste A, Pulkki K, Kallajoki M, Parvinen M, Voipio-Pulkki LM. Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res 2000;60:1789-92.
9. Billingham ME, Mason JW, Bristow MR, Daniels JR. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 1978;62:865-72.
10. Doroshow JH, Davies KJ. Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical. J Biol Chem 1986;261:3068-74.
11. Myers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger K, Young RC. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 1977;197:165-7.
12. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998;339:900-5.
13. Jiang B, Zhang L, Wang Y et al. Tanshinone IIA sodium sulfonate protects against cardiotoxicity induced by doxorubicin in vitro and in vivo. Food Chem Toxicol 2009;47:1538-44.
14. Kumar D, Kirshenbaum LA, Li T, Danelisen I, Singal PK. Apoptosis in adriamycin cardiomyopathy and its modulation by probucol. Antioxid Redox Signal 2001;3:135-45.
15. Liu X, Chen Z, Chua CC et al. Melatonin as an effective protector against doxorubicin-induced cardiotoxicity. Am.J.Physiol Heart Circ Physiol 2002;283:H254-H263.
16. Nazeyrollas P, Prevost A, Baccard N, Manot L, Devillier P, Millart H. Effects of amifostine on perfused isolated rat heart and on acute doxorubicin-induced cardiotoxicity. Cancer Chemother Pharmacol 1999;43:227-32.
17. Granger CB. Prediction and prevention of chemotherapy-induced cardiomyopathy: can it be done? Circulation 2006;114:2432-3.
18. Kukreja RC, Ockaili R, Salloum F, Xi L. Sildenafil-induced cardioprotection in rabbits. Cardiovasc Res 2003;60:700-1.
19. Ockaili R, Salloum F, Hawkins J, Kukreja RC. Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits. Am J Physiol Heart Circ Physiol 2002;283:H1263-H1269.
20. Salloum F, Yin C, Xi L, Kukreja RC. Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart. Circ Res 2003;92:595-7.
21. Fisher PW, Salloum F, Das A, Hyder H, Kukreja RC. Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 2005;111:1601-10.
22. Koka S, Das A, Zhu SG, Durrant D, Xi L, Kukreja RC. Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect. J Pharmacol Exp Ther 2010;334:1023-30.
23. Kuan J, Brock G. Selective phosphodiesterase type 5 inhibition using tadalafil for the treatment of erectile dysfunction. Expert Opin Investig Drugs 2002;11:1605-13.
24. Kouvelas D, Goulas A, Papazisis G, Sardeli C, Pourzitaki C. PDE5 inhibitors: in vitro and in vivo pharmacological profile. Curr Pharm Des 2009;15:3464-75.
25. Kukreja RC, Ockaili R, Salloum F et al. Cardioprotection with phosphodiesterase-5 inhibition--a novel preconditioning strategy. J Mol Cell Cardiol 2004;36:165-73.
26. Kukreja RC, Salloum F, Das A et al. Pharmacological preconditioning with sildenafil: Basic mechanisms and clinical implications. Vascul Pharmacol 2005;42:219-32.
27. Das A, Xi L, Kukreja RC. Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. J Biol Chem 2005;280:12944-55.
28. Childs AC, Phaneuf SL, Dirks AJ, Phillips T, Leeuwenburgh C. Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax ratio. Cancer Res 2002;62:4592-8.
29. Heling A, Zimmermann R, Kostin S et al. Increased expression of cytoskeletal, linkage, and extracellular proteins in failing human myocardium. Circ Res 2000;86:846-53.
30. Weisleder N, Taffet GE, Capetanaki Y. Bcl-2 overexpression corrects mitochondrial defects and ameliorates inherited desmin null cardiomyopathy. Proc Natl Acad Sci U.S.A 2004;101:769-74.
31. Wang X, Osinska H, Dorn GW et al. Mouse model of desmin-related cardiomyopathy. Circulation 2001;103:2402-7.
32. Oka T, Maillet M, Watt AJ et al. Cardiac-specific deletion of Gata4 reveals its requirement for hypertrophy, compensation, and myocyte viability. Circ Res 2006;98:837-45.
33. Aries A, Paradis P, Lefebvre C, Schwartz RJ, Nemer M. Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity. Proc Natl Acad Sci U.S.A 2004;101:6975-80.
34. Yen HC, Oberley TD, Vichitbandha S, Ho YS, St Clair DK. The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice. J Clin Invest 1996;98:1253-60.
35. Fernandes MA, Marques RJ, Vicente JA et al. Sildenafil citrate concentrations not affecting oxidative phosphorylation depress H2O2 generation by rat heart mitochondria. Mol Cell Biochem 2008;309:77-85.
36. Serarslan Y, Yonden Z, Ozgiray E et al. Protective effects of tadalafil on experimental spinal cord injury in rats. J Clin Neurosci 2010;17:349-52.
37. Salloum FN, Abbate A, Das A et al. Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. Am J Physiol Heart Circ Physiol 2008;294:H1398-H1406.
38. Takimoto E, Champion HC, Li M et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005;11:214-22.